| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/14/2002 | WO2002011765A1 COMBINATION PREPARATION WITH AN ERβ SELECTIVE ESTROGEN AND A SERM OR ANTIESTROGEN |
| 02/14/2002 | WO2002011741A1 Cardioplegic solution |
| 02/14/2002 | WO2002011735A2 Association of a purine activity and a nonsteroidal anti-inflammatory anti-inflammatory drug for treating sexual dysfunction |
| 02/14/2002 | WO2002011733A1 Pharmaceutical composition comprising condensed indole compound |
| 02/14/2002 | WO2002011724A2 Neuroprotective 2-pyridinamine compositions and related methods |
| 02/14/2002 | WO2002011715A2 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/14/2002 | WO2002011714A2 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 02/14/2002 | WO2002011710A2 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 02/14/2002 | WO2002011703A1 Hybrid neuroprosthesis for the treatment of brain disorders |
| 02/14/2002 | WO2002011665A2 Association of a purine and a nonsteroidal anti-inflammatory drug for treating sexual dysfunction |
| 02/14/2002 | WO2002011551A2 Oil/fat composition |
| 02/14/2002 | WO2001098471A8 Human phosphodiesterases |
| 02/14/2002 | WO2001081415A9 Parathyroid hormone and parathyroid hormone-related protein antagonists |
| 02/14/2002 | WO2001076531A3 Bile acid containing prodrugs with enhanced bioavailability |
| 02/14/2002 | WO2001072328A3 Methods of treating diseases with activated protein c |
| 02/14/2002 | WO2001068670A3 Family of mechanically sensitive human potassium channels activated by polyunsaturated fatty acids and use thereof |
| 02/14/2002 | WO2001068603A3 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
| 02/14/2002 | WO2001064874A3 Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 02/14/2002 | WO2001064008A3 Vaccine for the treatment of artherosclerosis |
| 02/14/2002 | WO2001062954A8 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
| 02/14/2002 | WO2001058921A3 Methods and compositions for generating angiostatin |
| 02/14/2002 | WO2001058462A3 Models, methods and materials relating to clinical conditions associated with reactive oxygen species |
| 02/14/2002 | WO2001057210A3 Use of dendroaspin as a vehicle for non-dendroaspin domains |
| 02/14/2002 | WO2001057021A3 2-[1H]-QUINOLONE AND 2-[1H]-QUINOXALONE INHIBITORS OF FACTOR Xa |
| 02/14/2002 | WO2001056598A3 Methods for preventing or attenuating pathoangiogenic conditions by using gbs-toxin (cm101) |
| 02/14/2002 | WO2001049685A3 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 02/14/2002 | WO2001045725A3 Treatment for inflammatory bowel disease (ibd) and related conditions |
| 02/14/2002 | WO2001042288A3 G-protein coupled receptors |
| 02/14/2002 | WO2001041807A3 Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 02/14/2002 | WO2001034088A3 Cardiac device for electrical and chemical regulation, and vasoactive intestinal peptide for treatment of cardiopulmonary disorders |
| 02/14/2002 | WO2001032695A3 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF |
| 02/14/2002 | WO2001029055A3 Novel oligosaccharides, preparation method and pharmaceutical compositions containing same |
| 02/14/2002 | WO2001014418A3 p193 PROTEINS AND NUCLEIC ACIDS, AND USES THEREOF |
| 02/14/2002 | WO2000061188A9 Sodium channel blocker compositions and the use thereof |
| 02/14/2002 | US20020019563 A S-(2-(1-iminoethyl)amino)ethyl)-2-methyl-L-cysteine |
| 02/14/2002 | US20020019540 Conformationally constrained compounds as pharmaceutical agents |
| 02/14/2002 | US20020019537 Novel processes for preparing torsemide intermediate |
| 02/14/2002 | US20020019534 Gem substituted hydroxamic acids |
| 02/14/2002 | US20020019533 Piperidine derivatives and anti-platelet agents containing the same |
| 02/14/2002 | US20020019530 Antitumor agent |
| 02/14/2002 | US20020019519 KIAA0551 polynucleotides and polypeptides use |
| 02/14/2002 | US20020019515 Novel spoIIIE |
| 02/14/2002 | US20020019424 1-sulfonyl pyrrolidine derivatives |
| 02/14/2002 | US20020019416 Esters and amides as pla2 inhibitors |
| 02/14/2002 | US20020019411 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| 02/14/2002 | US20020019406 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands |
| 02/14/2002 | US20020019404 Anticancer agents, skin disorders |
| 02/14/2002 | US20020019402 Integrin inhibitors and their methods of use |
| 02/14/2002 | US20020019393 Treating inflammation, autoimmune diseases, destructive bone disorders, proliferative disorders, infections, neurvous system disorders, reperfusion/ischemia in stroke, cardiovascular disorders, hypoxia, edema, fever, pain |
| 02/14/2002 | US20020019392 By administering indole compounds such as 1-(4-(2-Azepan-1yl-ethoxy)-benzyl)-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5 -ol; epilepsy, asthma, eating disorders, obesity, neurodegenertive conditions, schizophrenia |
| 02/14/2002 | US20020019391 Combinations of statins and estrogenic agents |
| 02/14/2002 | US20020019390 Imidazole and imidazoline derivatives and uses thereof |
| 02/14/2002 | US20020019386 5-HT4 receptor antagonists |
| 02/14/2002 | US20020019367 Compositions and methods for modulation of vascular structure and/or function |
| 02/14/2002 | US20020019360 Treatment for cardiovascular disease |
| 02/14/2002 | US20020019350 Targeted angiogenesis |
| 02/14/2002 | US20020019346 Treatment of prostate cancer by inhibiting lyn tyrosine kinase |
| 02/14/2002 | US20020019000 Polynucleotides coexpressed with matrix-remodeling genes |
| 02/14/2002 | US20020018821 Process for the purification of a red fruit extract containing anthocyanosides, extract obtained from the process and use of said extract |
| 02/14/2002 | US20020018807 Mixture of cocoa plant extract and antichloesterol agent |
| 02/14/2002 | US20020018752 Ablation disease by cutting, blocking blood supply to tissue |
| 02/14/2002 | DE10038640A1 Präparat mit gefäßschützender und antioxidativer Wirkung sowie dessen Verwendung Preparation with vascular protective and antioxidant activity and its use |
| 02/14/2002 | DE10036871A1 Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe Dispersions for the formulation of poorly soluble drugs or little |
| 02/14/2002 | CA2420066A1 Use, in combination, of a purine activity and a nonsteroidal anti-inflammatory drug for preparing an anti-thrombotic and/or anti-inflammatory drug |
| 02/14/2002 | CA2419062A1 Methods for culturing human lung mast cells and uses thereof |
| 02/14/2002 | CA2419042A1 Medicine for fighting against sexual dysfunction |
| 02/14/2002 | CA2419036A1 Non-imidazole aryloxypiperidines as h3 receptor ligands |
| 02/14/2002 | CA2419027A1 Bicyclic compounds as h3 receptor ligands |
| 02/14/2002 | CA2418995A1 Lactam compounds and their use as inhibitors of serine proteases and method |
| 02/14/2002 | CA2418952A1 A novel member of the lysyl oxidase gene family |
| 02/14/2002 | CA2418951A1 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 02/14/2002 | CA2418946A1 Pharmaceutical form comprising a cell regulating factor and/or a cell proliferation promoter |
| 02/14/2002 | CA2418936A1 Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis |
| 02/14/2002 | CA2418912A1 Neuroprotective 2-pyridinamine compositions and related methods |
| 02/14/2002 | CA2418904A1 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation |
| 02/14/2002 | CA2418895A1 Biphenyl derivatives and their use as ppar-gamma receptor activators |
| 02/14/2002 | CA2418386A1 Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein |
| 02/14/2002 | CA2418369A1 Non-imidazole aryloxyalkylamines as h3 receptor ligands |
| 02/14/2002 | CA2418144A1 Urocortin proteins and uses thereof |
| 02/14/2002 | CA2417914A1 Cyclic oxyguanidine protease inhibitors |
| 02/14/2002 | CA2417828A1 Tartrate salts of thiazolidinedione derivative |
| 02/14/2002 | CA2417784A1 Pyrrolotriazolopyrimidinone derivatives |
| 02/14/2002 | CA2417755A1 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 02/14/2002 | CA2417587A1 Transporters and ion channels |
| 02/14/2002 | CA2417098A1 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/14/2002 | CA2416525A1 Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| 02/14/2002 | CA2415469A1 Quinoline derivatives having vegf inhibiting activity |
| 02/14/2002 | CA2415467A1 Novel n-(2-phenyl-3-aminopropyl)naphtamides |
| 02/14/2002 | CA2415022A1 Cinnoline compounds |
| 02/14/2002 | CA2412368A1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 02/14/2002 | CA2411928A1 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclindependent kinases |
| 02/14/2002 | CA2386103A1 Vascular endothelial growth factor 2 |
| 02/13/2002 | EP1179541A1 Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| 02/13/2002 | EP1179182A2 Diagnosis and treatment of atherosclerosis and coronary heart disease |
| 02/13/2002 | EP1179065A2 Full-length molecules expressed in human tissues |
| 02/13/2002 | EP1179064A2 Secreted polypeptides and corresponding polynucleotides |
| 02/13/2002 | EP1179052A2 Serine proteases |
| 02/13/2002 | EP1179018A1 Interaction between the vhl tumour suppressor and hypoxia inducible factor, and assay methods relating thereto |
| 02/13/2002 | EP1179005A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy |
| 02/13/2002 | EP1178993A1 Thiazoloderiatives and pharmaceutical compositions containing them |